Related Experiment Video
Updated: Oct 17, 2026

Analytical Techniques for Assaying Nitric Oxide Bioactivity
Published on: June 18, 2012
Nitric oxide release from half-sandwich Ru(II)-p-cymene acylthiourea nitrite complexes: antiproliferative activities
Amir Karim1, Rahime Eshaghi Malekshah1, Miao-Chu Tseng2,3
1Department of Medicinal and Applied Chemistry, College of Life Science, Kaohsiung Medical University, Kaohsiung 807378, Taiwan. sodiohsu@gap.kmu.edu.tw.
Abstract:
In half-sandwich Ru(II)-p-cymene frameworks, the labile chlorido ligand can readily undergo substitution by various donor groups such as triphenylphosphine, azide, or a nitro group. In the present study, we report for the first time the incorporation of a nitrito (NO2-) ligand into an acylthiourea-based Ru(II)-p-cymene system. The six Ru(II)-p-cymene complexes comprising chlorido derivatives L1RuCl-L3RuCl (1a-3a) and nitrite-bound analogues L1RuNO2-L3RuNO2 (1b-3b) were synthesized under distinct reaction conditions and fully characterized. The molecular structures of complexes 1b and 2b were established by single-crystal X-ray diffraction analysis, while FT-IR, UV-Vis, and 1H/13C NMR spectroscopic studies clearly differentiated the coordination of the two co-ligands. A nitric oxide release study was performed chemically using (TPP)Co as an NO trapping agent, showing >70% NO release in an acidic environment for 1b and 2b. The antiproliferative activity of Ru-nitro complexes was greater than that of precursor Ru-chloride complexes in both TNBC (HCC1937) and non-TNBC (SKBR-3) cells. In the TNBC line, complexes 1b and 2b showed the lowest IC50 values (8.55 ± 1.00 and 7.47 ± 0.95 μM) and induced higher caspase-3/7 apoptotic activity than L1 and L2, which themselves produced greater activity than 1a and 2a. In vasorelaxation studies, 1b and 2b showed pronounced relaxation, achieving 85.48 ± 7.47% and 77.18 ± 4.97%, which are significantly greater than their chlorido complexes. DFT-D3 calculations were also performed to evaluate NO and OH release for all complexes, revealing that complex 2b exhibited higher NO-release, consistent with its observed anticancer activity.
More Related Videos
Related Concept Videos
Nitric Oxide Signaling Pathway
Antihypertensive Drugs: Vasodilators
Antianginal Drugs: Nitrates and β-Blockers
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Treatment for Pulmonary Arterial Hypertension: Phosphodiesterase Inhibitors
Among the PDE5 inhibitors, sildenafil (Revatio) stands out as a competitive and selective inhibitor. It operates by elevating cellular levels of cGMP and augmenting signaling through the cGMP-PKG pathway, promoting vasodilation. Upon oral...

